Parse Biosciences Launches Laboratory Automation Provider Program, Collaborates with Hamilton, Opentrons Labworks, SPT Labtech
April 24 2024 - 8:15AM
Business Wire
Program will support faster insights for
large-scale studies and drug development
Parse Biosciences, a leading provider of accessible and scalable
single cell sequencing solutions, today announced it has launched
its Laboratory Automation Provider Program, enabling automation
providers to readily support the adoption of Parse’s Evercode™
single cell products. By combining powerful automation with the
Parse Evercode platform, customers will have unprecedented access
to high-throughput single cell sequencing, enabling them to rapidly
generate insights for large-scale studies.
Parse’s Evercode single cell technology has enabled researchers
to scale their projects to millions of cells or nuclei and has been
widely adopted across oncology, immunology, neuroscience, basic
research, and drug and target discovery. To facilitate scaling up
these projects and to help researchers generate insights more
quickly, Parse has developed automation-friendly workflows for
high-throughput sample fixation, single cell barcoding, and library
preparation.
As key providers in the new Laboratory Automation Provider
Program, Hamilton, Opentrons, and SPT Labtech will each collaborate
with Parse to automate Parse’s Evercode Whole Transcriptome and
Whole Transcriptome Mega workflows on their respective liquid
handling platforms. These customized scripts will allow users to
purchase application-ready instruments and empower existing users
to more easily adapt Parse workflows in their labs.
“Parse is focused on providing complete, end-to-end solutions at
unprecedented scale. By joining with some of the industry's top
automation providers, we are giving customers more extensive
choices,” said Parse Biosciences co-founder and CEO Alex Rosenberg.
“This approach is fundamental to our core belief that single cell
RNA sequencing provides valuable insights that should be available
to all scientists, whether they're in basic research or in a
high-throughput drug development environment.”
Hamilton, Opentrons, and SPT Labtech provide versatile liquid
handling platforms that support many workflows, in addition to
Evercode, providing flexibility and economy to customers who run
other protocols in their labs. The companies aim to have automated
protocols for the Evercode platform available in coming months.
About Parse Biosciences
Parse Biosciences is a global life sciences company whose
mission is to accelerate progress in human health and scientific
research. Empowering researchers to perform single cell sequencing
with unprecedented scale and ease, its pioneering approach is
enabling groundbreaking discoveries in cancer treatment, tissue
repair, stem cell therapy, kidney and liver disease, brain
development, and the immune system.
Founded based on a transformative technology invented at the
University of Washington, Parse has raised over $100 million and is
used by over 1,700 labs across the world. Its growing portfolio of
products includes Evercode Whole Transcriptome, Evercode TCR,
CRISPR Detect, Gene Capture, and a software tool for data
analysis.
Headquartered in Seattle, Washington’s vibrant South Lake Union
district, Parse Biosciences recently opened a 34,000 square foot
headquarters and state-of-the-art laboratory.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240424893659/en/
Jay Roberts, SRPR jay@shevrushpr.com | 917.696.2142